The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients

American Journal of Nephrology

Volumn 23, Issue 5, 2003, Pages 307-314

  Chertow, Glenn M ^a,b,k   Raggi, Paolo ^c   McCarthy, James T ^d   Schulman, Gerald ^e   Silberzweig, Jeffrey ^f   Kuhlik, Amy ^g   Goodman, William G ^h   Boulay, Amy ⁱ   Burke, Steven K ⁱ   Toto, Robert D ^j  

^a UCSF Medical Center at Parnassus   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f Department of Obstetrics Gynecology   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ GENZYME CORPORATION   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Arteriosclerosis; Calcification; Calcium; Clinical trial; Sevelamer

Indexed keywords

ALBUMIN; CALCIUM; CALCIUM ACETATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ADULT; AORTA ATHEROSCLEROSIS; ARTHRALGIA; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; COUGHING; DIARRHEA; DISEASE EXACERBATION; DRUG EFFECT; DYSPNEA; FEMALE; FOLLOW UP; HEADACHE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ACETATES; ADULT; AORTIC DISEASES; ARTERIOSCLEROSIS; CALCINOSIS; CALCIUM; EPOXY COMPOUNDS; FEMALE; HUMANS; HYPERCALCEMIA; MALE; MIDDLE AGED; PHOSPHATES; POLYAMINES; POLYETHYLENES; RENAL DIALYSIS; STATISTICS, NONPARAMETRIC;

EID: 10744227063     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072822     Document Type: Article

References (40)

1. Indridason OS, Quarles LD: Hyperphosphatemia in end-stage renal disease. Adv Ren Replace Ther 2002;9:184-192.
2. Llach F, Velasquez Forero F: Secondary hyperparathyroidism in chronic renal failure: Pathogenic and clinical aspects. Am J Kidney Dis 2001;38(5 Suppl 5):20-33.
3. Locatelli F, Cannata-Andia JB, Drüke TB, Horl WH, Ritz E: Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002;17:723-731.
4. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM: The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002;13:2762-2769.
5. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998;31:607-617.
6. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-482.
7. Marchais SJ, Metivier F, Guérin AP, London GM: Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999;14:2178-2183.
8. Bardin T: Musculoskeletal manifestations of chronic renal failure. Curr Opin Rheumatol 2003;15:48-54.
9. Clarkson EM, McDonald SJ, de Wardener HE: The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci 1966;30:425-438.
10. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315:157-161.
11. Mactier RA, Van Stone J, Cox A, Van Stone M, Twardowski Z: Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 1987;28:222-226.
12. Fournier A, Morinière P, Ben Hamida F, el Esjer N, Shenovda M, Ghazali A, Bouzernidj M, Achard JM, Westeel PFl: Use of alkaline calcium salts as phosphate binder in uremic patients. Kidney Int Suppl 1992;38:50-61.
13. Malluche HH, Monier-Faugere MC: Hyperphosphatemia: Pharmacologic intervention yesterday, today and tomorrow. Clin Nephrol 2000;54:309-317.
14. Saupe J, Belmega G, Krause R, Bennhold I: Management of hyperphosphatemia with calcium citrate in hemodialysis patients. Nephron 1989;52:93-94.
15. Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB: Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991;17:544-550.
16. Bro S, Rasmussen RA, Handberg J, Olgaard K, Feldt-Rasmussen B: Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am J Kidney Dis 1998;31:257-262.
17. Birck R, Zimmermann E, Wassmer S, Nowack R, van der Woude FJ: Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: A cross-over study. Nephrol Dial Transplant 1999;14:1475-1479.
18. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
19. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS: Reduction of dietary phosphorus absorption by phosphorus binders: A theoretical, in vitro, and in vivo study. J Clin Invest 1989;83:66-73.
20. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller LR, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989;36:690-695.
21. Canavese C, Bergamo D, Dib H, Bermond F, Burdese M: Calcium on atrial: Beyond a reasonable doubt? Kidney Int 2003;63:381-382.
22. Fournier A, Benyahia M, Claudia CP, Sadek T: Calcium on trial: Beyond a reasonable doubt? Kidney Int 2003;63:382-383.
23. Cleveland M: Calcium on trial: Beyond a reasonable doubt? Kidney Int 2003;63:383.
24. Nolan CR, Quinibi WY: Calcium on trial: Beyond a reasonable doubt? Kidney Int 2003;63:383.
25. Friedewald W, Levy R, Fredrickson D: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
26. Nauck M, Kramer-Guth A, Bartens W, Marz W, Wieland H, Wanner C: Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients? Clin Nephrol 1996;46:319-325.
27. Achenbach S, Ropers D, Mohlenkamp S, Schmermund A, Muschiol G, Groth J, Kusus M, Regenfus M, Daniel WG, Erbel R, Moshage W: Variability of repeated coronary artery calcium measurements by electron beam tomography. Am J Cardiol 2001;87:210-213.
28. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R: Quantification of coronary artery calcium using ultra-fast computed tomography. J Am Coll Cardiol 1990;15:827-832.
29. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients: A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
30. Caravaca F, Santos I, Cubero JJ, Esparrago JF, Arrobas M, Pizarro JL, Robles R, Sanchez-Casado E: Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron 1992;60:423-427.
31. Ring T, Nielsen C, Andersen SP, Behrens JK, Sodemann B, Kornerup HJ: Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: A controlled study. Nephrol Dial Transplant 1993;8:341-346.
32. Pflanz S, Henderson IS, McElduff N, Jones MC: Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant 1994;9:1121-1124.
33. Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP: Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 1996;45:111-119.
34. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998;339:1972-1978.
35. Guérin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-1021.
36. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
37. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H: Vascular calcification and inorganic phosphate. Am J Kidney Dis 2001;38(4 Suppl 1):34-37.
38. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-E17.
39. Undas A, Brozek J, Musial J: Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin Lab 2002;48:287-296.
40. Ansell BJ, Watson KE, Weiss RE, Fonarow GC: hsCRP and HDL Effects of Statins Trial (CHEST): Rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation. Heart Dis 2003;5:2-7.